A majority of patients with plaque psoriasis had at least 75% improvement, and complete or near-complete clearance by physician assessment, after 16 weeks in two randomized trials of the TYK2 ...
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, ...
Please provide your email address to receive an email when new articles are posted on . In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results